Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Lipid Nanoparticle Formulation for Gene Editing and RNA-Based Therapies for Glioblastoma

[Neuro-Oncology] Researchers developed lipid nanoparticles encapsulating Cas9 mRNA and a miR-10b-targeting sgRNA.

Bispecific Killer Cell Engager-Secreting CAR-T Cells Redirect Natural Killer Specificity to Enhance Antitumor Responses

[Nature Biomedical Engineering] Scientists used bicistronic vectors to co-express chimeric antigen receptors and secreted immune cell engagers, leveraging the combined therapeutic potential of both effector cell types.

Transabdominal Ultrasound Guided AAV9-GFP Delivery in Fetal Pigs: A Translational and Minimally Invasive Model for In Utero Fetal Gene Therapy

[Gene Therapy] The authors established and validated a minimally invasive, ultrasound-guided approach for systemic gene delivery in fetal pigs using a self-complementary AAV9 vector encoding GFP under a CAG promoter.

CAR-T Cells Containing CD28 Versus 4-1BB Co-Stimulatory Domains Show Distinct Metabolic Profiles in Patients

[Cell Reports] The authors studied the metabolic characteristics induced by CD28 versus 4-1BB co-stimulation in patient CAR-T cells ex vivo.

Immunogenicity of Autologous and Allogeneic Human Primary Cholangiocyte Organoid Cellular Therapies

[Cell Reports Medicine] Researchers used in vitro co-cultures and in vivo humanized mouse experimental models to examine autologous and allogeneic immune response to human primary cholangiocyte organoids as treatment for bile duct disorders.

Dynamically Covalent Lipid Nanoparticles Mediate CRISPR-Cas9 Genome Editing against Choroidal Neovascularization in Mice

[Science Advances] Dynamically covalent lipid nanoparticles were engineered to mediate vascular endothelial growth factor A (VEGFA) gene editing and choroidal neovascularization treatment by codelivering Cas9 mRNA and single guide RNA targeting VEGFA.

Surface Downmodulation of TIM3 Safeguards Healthy Cells but Not Acute Myeloid Leukemia from CAR T-Cell Therapy

[HemaSphere] Scientists explored the feasibility of targeting TIM3 with CAR T-cells. TIM3 CAR T-cells were successfully generated from different healthy individuals with excellent in vitro expansion without signs of fratricide and sustained central-memory phenotype with minimal expression of exhaustion-related markers.

Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma

[Blood Advances] Researchers analyzed 10 heavily pretreated multiple myeloma patients at three medical centers treated with the commercially approved CAR-T product ide-cel in a real-world setting.

Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens

[Blood] Investigators identified B cell maturation antigen as a highly short-lived protein that undergoes K48-linked polyubiquitylation at the plasma membrane, leading to its p97-dependent degradation via the ubiquitin-proteasome system.

CAR-T Cell Therapy for Cancer: Current Challenges and Future Directions

[Signal Transduction and Targeted Therapy] The authors provide a comprehensive overview of CAR-T cell therapy for cancer, covering the structure of CAR-T cells and the history of their clinical application.

CRISPR-Based Therapeutic Genome Editing for Inherited Blood Disorders

[Nature Reviews Drug Discovery] Investigators explore the state-of-the-art genome editing technologies of nucleases, base editors and prime editors, which hold promise to address unmet clinical needs for patients with inherited haematological disorders.

Research Leaders across New York State Form Empire State Cellular Therapy Consortium

[Roswell Park] Roswell Park Comprehensive Cancer Center, the University of Rochester Wilmot Cancer Institute,and The Icahn School of Medicine, NYU Langone Health, and Weill Cornell Medicine have partnered to launch the Empire State Cellular Therapy Consortium.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

spot_img